Clinical Trials Logo

Plexiform Neurofibroma clinical trials

View clinical trials related to Plexiform Neurofibroma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06188741 Not yet recruiting - Neurofibromatosis 1 Clinical Trials

Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1

NF114
Start date: August 1, 2024
Phase: Phase 2
Study type: Interventional

Plexiform neurofibromas (PN) are known to cause significant morbidity in children with NF1. The recent FDA approval for selumetinib in children 2 years and older with inoperable symptomatic PN was based on the finding that selumetinib shrinks the majority of PN in children with NF1 and results in clinically meaningful benefit such as improvement in pain or range of motion. However, many morbidities, such as blindness or nerve damage, cannot be fully reversed with PN shrinkage. Therefore, there remains a critical need in this patient population to determine if young participants with PN in high-risk locations may benefit from early medical intervention prior to the development of clinical problems. This study will determine whether participants with asymptomatic PN in high-risk locations can potentially benefit from early treatment with selumetinib.